Phase 4CompletedAge-related condition

The Effect of Vitamin K2 on Bone Turnover

Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study

Sponsor
Eisai Limited (Industry)
Enrollment
131 enrolled
Conditions
Osteoporosis
Interventions
Menatetrenone (Vitamin K2)
Ages
adults, older adults
Registry
NCT00548509

Full record on ClinicalTrials.gov

From the registry

To investigate the effect of menatetrenone on bone turnover in postmenopausal patients with osteoporosis. One month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin. Moderate increases of bone resorption and formation markers were observed after 6 months. These changes may contribute to fracture prevention in patients with osteoporosis.

Primary outcomes

  • Gamma-carboxylation

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started